A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease.
Sensitive, non-invasive biomarkers that facilitate Parkinson's disease (PD) detection and stage assignment are currently unavailable. The objective of this study is to investigate the potential of circulating microRNAs (miRNAs) as novel biomarkers for PD. Solexa sequencing technology and quantitative real-time PCR were applied to screen and verify altered serum miRNAs in PD patients. Serum miR-141, miR-214, miR-146b-5p, and miR-193a-3p were decreased significantly in PD patients compared with controls. Furthermore, the 4-miRNA panel enabled the differentiation of HY stage 1 and 2 PD patients from controls. The four serum miRNAs may represent novel biomarkers for the early detection of PD.